Pricing
Growing criticism over stratospheric cost of spinal muscular atrophy-fighting drug Zolgensma ignores trade-off value
Novartis recently won FDA approval for Zolgensma, a new medicine that can potentially cure infants suffering from the otherwise fatal ...
Gene therapy could be revolutionary—if we can figure out how to pay for it
Dozens of revolutionary gene therapies that mend faulty strands of DNA are on their way, bringing the power to eliminate ...